Analytical Validation of a Pan-Cancer Next-Generation Sequencing Assay for In-House Liquid Biopsy Testing: An International Multicenter Study.

doi:10.1016/j.jmoldx.2025.08.008

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Analytical Validation of a Pan-Cancer Next-Generation Sequencing Assay for In-House Liquid Biopsy Testing: An International Multicenter Study.

The Journal of molecular diagnostics : JMD - 1 Dec 2025

Lescuyer Gaëlle, Harlé Alexandre, Kumar Hari Shankar, Constantoulakis Pantelis, Pfarr Nicole, Heitzer Ellen, Michon Clémence, Russo Gianluca, Speel Ernst-Jan M, Piecyk Marie, Husson Marie, Christopoulou Georgia, Mayr Eva-Maria, Koppermann Mai-Lan, Passot Christophe, Graf Ricarda, Aoul Anes Hadjadj, Bourdon Violaine, Dubbink Hendrikus J, van Marion Ronald, Demers Imke, Dingemans Anne-Marie C, Troncone Giancarlo, Pepe Francesco, Muinelo-Romay Laura, Díaz-Lagares Ángel, Rodriguez-Casanova Aitor, Lago Lestón Ramón Manuel, Pathak Deepak, Shah Parth, Parillaud Romain V, Martínez de Ilarduya Oskar, Behr Jonas, Rapin Alexis, Vetterli Thomas, Boppudi Sanga Mitra, Malapelle Umberto, Payen Léa

Abstract excerpt

Liquid biopsy assays are transforming precision oncology by providing a less invasive alternative to tissue biopsies. These assays screen for tumor genetic alterations in circulating free DNA, which typically requires detecting variants at low allele frequencies and, therefore, a high sensitivity and specificity. This international, multicenter analytical performance study evaluated the Hedera Profiling 2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Circulating Tumor DNA

Share to DNA Copy Number Variations

Share to High-Throughput Nucleotide Sequencing

Share to Liquid Biopsy

Share to Microsatellite Instability

Share to Reproducibility of Results

Share to Sensitivity and Specificity

Source

Open in PubMed

Identifiers

PMID: 41015181
DOI: 10.1016/j.jmoldx.2025.08.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analytical Validation of a Pan-Cancer Next-Generation Sequencing Assay for In-House Liquid Biopsy Testing: An International Multicenter Study.PMID 41015181Read ↗

Analytical Validation of a Pan-Cancer NGS Assay for In-House Liquid Biopsy Testing: An International Multicenter StudySemantic proximity Read ↗

Development and Performance Validation of a Comprehensive Liquid Biopsy Genotyping Panel for Pan-cancer Analysis.Semantic proximity Read ↗

Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing-Based Comprehensive Tumor Profiling in Liquid Biopsy Samples.Semantic proximity Read ↗

Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNASemantic proximity Read ↗

A liquid biopsy-centered, pan-cancer, open next generation sequencing panel to support clinical decision-making (LION panel)Semantic proximity Read ↗

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNASemantic proximity Read ↗

Validation of a DNA-Based Next-Generation Sequencing Test for Molecular Diagnostic Variant and Fusion Detection in Formalin-Fixed, Paraffin-Embedded Tissue Specimens and Liquid Biopsy Plasma/Cell-Free DNA Samples.Semantic proximity Read ↗

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNASemantic proximity Read ↗

Validation and clinical evaluation of a comprehensive circulating tumor DNA assay for genomic profiling in solid tumorsSemantic proximity Read ↗

Analytical and Clinical Validation of an Amplicon-based Next Generation Sequencing Assay for Ultrasensitive Detection of Circulating Tumor DNASemantic proximity Read ↗

Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.Semantic proximity Read ↗

Liquid biopsies across the cancer care continuum.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.